Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials by Cesne, A L, Judson, I, Maki, R, Grosso, F, Schuetze, S, Mehren, M V, Chawla, S P, Demetri, G D, Nieto, A, Tanovic, A, Blay, J-Y

Get full text

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial by DeMatteo, Ronald P, Prof, Ballman, Karla V, PhD, Antonescu, Cristina R, MD, Maki, Robert G, MD, Pisters, Peter WT, Prof, Demetri, George D, MD, Blackstein, Martin E, MD, Blanke, Charles D, Prof, von Mehren, Margaret, MD, Brennan, Murray F, Prof, Patel, Shreyaskumar, Prof, McCarter, Martin D, MD, Polikoff, Jonathan A, MD, Tan, Benjamin R, MD, Owzar, Kouros, PhD

Get full text

Pharmacovigilance Using Clinical Notes by LePendu, P, Iyer, S V, Bauer-Mehren, A, Harpaz, R, Mortensen, J M, Podchiyska, T, Ferris, T A, Shah, N H

Get full text

A Single-Arm Phase 2 Trial of Trametinib in Patients with Locally Advanced or Metastatic Epithelioid Hemangioendothelioma by Schuetze, Scott M, Ballman, Karla V, Heise, Rachel, Ganjoo, Kristen N, Davis, Elizabeth J, George, Suzanne, Burgess, Melissa A, Choy, Edwin, Shepard, Dale R, Tinoco, Gabriel, Hirbe, Angela, Kelly, Ciara M, Attia, Steven, Deshpande, Hari A, Schwartz, Gary K, Siontis, Brittany L, Riedel, Richard F, von Mehren, Margaret, Kozlowski, Erin, Chen, Helen X, Astbury, Caroline, Rubin, Brian P

Get full text

Phase II SWOG-directed Intergroup Trial (S0505) of Sorafenib in Advanced Soft Tissue Sarcomas by von Mehren, M., Rankin, C., Goldblum, J.R., Demetri, G.D., Bramwell, V., Ryan, C.W., Borden, E.

Get full text

Beta-Decay Half-Lives and Neutron-Emission Probabilities of Very Neutron-Rich Y to Tc Isotopes by Mehren, T, Pfeiffer, B, Schoedder, S, Kratz, K, Huhta, M, Dendooven, P, Honkanen, A, Lhersonneau, G, Oinonen, M, Parmonen, J, Penttilä, H, Popov, A, Rubchenya, V, V, Äystö, J

Get full text

7517 POSTER Clinical tolerability of trabectedin administered by two different schedules (weekly for 3 of 4 weeks vs q3 weeks) in patients with advanced/metastatic liposarcoma or l... by Chawla, S, Casali, P.G, von Mehren, M, Le Cesne, A, Blay, J.Y, Lebedinsky, C, Alfaro, V, Elsayed, Y, Michiels, B, Demetri, G.D

Get full text

Beta-decay studies of far from stability nuclei near N = 28 by Sorlin, O., Guillemaud-Mueller, D., Anne, R., Axelsson, L., Bazin, D., Böhmer, W., Borrel, V., Jading, Y., Keller, H., Kratz, K.-L., Lewitowicz, M., Lukyanov, S.M., Mehren, T., Mueller, A.C., Penionzhkevich, Yu.E., Pougheon, F., Saint-Laurent, M.G., Salamatin, V.S., Shoedder, S., Wöhr, A.

Get full text

First beta-decay studies of the neutron-rich isotopes $^{53-55}$Sc and $^{56-59}$V by Sorlin, O., Borrel, V., Grevy, S., Guillemaud-Mueller, D., Mueller, A.C., Pougheon, F., Boehmer, W., Kratz, K-L., Mehren, T., Moeller, P., Pfeiffer, B., Rauscher, T., Saint-Laurent, M.G., Anne, R., Lewitowicz, M., Ostrowski, A., Doerfler, T., Schmidt-Ott, W-D.

Get full text

First beta-decay studies of the neutron-rich isotopes 53–55Sc and 56–59V by Sorlin, O., Borrel, V., Grévy, S., Guillemaud-Mueller, D., Mueller, A.C., Pougheon, F., Böhmer, W., Kratz, K.-L., Mehren, T., Möller, P., Pfeiffer, B., Rauscher, T., Saint-Laurent, M.G., Anne, R., Lewitowicz, M., Ostrowski, A., Dörfler, T., Schmidt-Ott, W.-D.

Get full text

Neutron-rich isotopes Ti 54 − 57 by Dörfler, T., Schmidt-Ott, W.-D., Hild, T., Mehren, T., Böhmer, W., Möller, P., Pfeiffer, B., Rauscher, T., Kratz, K.-L., Sorlin, O., Borrel, V., Grévy, S., Guillemaud-Mueller, D., Mueller, A. C., Pougheon, F., Anne, R., Lewitowicz, M., Ostrowsky, A., Robinson, M., Saint-Laurent, M. G.

Get full text

Neutron-rich isotopes 54-57Ti by Dörfler, T, Schmidt-Ott, W, Hild, T, Mehren, T, Böhmer, W, Möller, P, Pfeiffer, B, Rauscher, T, Kratz, K, Sorlin, O, Borrel, V, V, Grévy, S, Guillemaud-Mueller, D, Mueller, AC, Pougheon, F, Anne, R, Lewitowicz, M, Ostrowsky, A, Robinson, M, Saint-Laurent, MG

Get full text